PREDICTORS OF POOR OUTCOME IN PAEDIATRIC CROHN’S DISEASE

(1) Biostatistics, Univ Lille Nord de France

(2) Epidemiology Unit, University and Hospital, Lille

(3) Gastroenterology Unit, Hospital and University Rouen, Rouen

(4) Gastroenterology Unit, Hospital and University Amiens, Amiens

(5) Gastroenterology Unit

(6) Paediatric Unit, University and Hospital, Lille

(7) Gastroenterology Unit, St Louis Hospital, Paris

(8) Biostatistics, University and Hospital, Lille, France



This item was part of the Safety and outcome prediction in IBD session at Gastro 2009 UEGW/WCOG London (17th UEGW)

This item can be cited as: Gut 2009; 58 (Suppl II) A32

You may be interested in:

Amgen - The emerging treatment landscape of IBD: role of innovator biologics and biosimilars (Amgen Europe GmbH)
English, Presentation, Industry Sponsored Symposia, Industry Sponsored Symposia, 2018, Amgen Europe GmbH
EFFICACY AND SAFETY OF ADALIMUMAB IN CHILDREN WITH CROHN’S DISEASE PREVIOUSLY TREATED WITH INFLIXIMAB.
English, Medical management, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013

Categorisation:

  • Format
    • Abstract
  • Language
    • English
  • Year
    • 2009